Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
18 June 2024
Learn more
Press Releases —
ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections
27 Mar 2024
Learn more
Press Releases —
ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP® (cefepime/enmetazobactam)
26 Jan 2024
Learn more
Press Releases —
ADVANZ PHARMA acquires global rights to Androcur® from Bayer
07 Nov 2023
Learn more
Press Releases —
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand
04 Oct 2023
Learn more
Press Releases —
ADVANZ PHARMA signs an exclusive agreement with GP Pharm for a peptide specialty injectable generic for multiple European countries
04 Sept 2023
Learn more
Press Releases —
ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2022-2023
01 Sept 2023
Learn more
Press Releases —
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe